Work

A phase II study of afatinib (BIBW 2992) in patients with advanced HER2-positive trastuzumab-refractory esophagogastric cancer.

Year: 2012

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2012.30.15_suppl.tps4144

Authors: Yelena Yuriy Janjigian, David Ilson, David Paul Kelsen, Mark Schattner, Adriana Heguy, Efsevia Vakiani

Institution: Memorial Sloan Kettering Cancer Center

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2593892075

Cites:

Cited by: 6

Related to: 10